Clinical Trial Results - The CheckMate -9ER trial demonstrated superior progression-free survival (PFS) and objective response rates (ORR) for Opdivo plus CABOMETYX compared to sunitinib in patients with advanced or metastatic renal cell carcinoma (RCC) [1][2] - Median PFS was 16.4 months for Opdivo plus CABOMETYX vs 8.4 months for sunitinib, with a hazard ratio (HR) of 0.58 [2] - Median overall survival (OS) was 46.5 months for Opdivo plus CABOMETYX vs 36.0 months for sunitinib, with an HR of 0.77 [2] - ORR was 55.7% for Opdivo plus CABOMETYX vs 27.7% for sunitinib, with complete response (CR) rates of 13.6% vs 4.6% respectively [2] - The combination showed durable benefits across patient subgroups, including intermediate-/poor-risk and favorable-risk groups [3][4] Safety and Efficacy - No new safety concerns were identified in the follow-up analysis, with any-grade treatment-related adverse events (TRAEs) occurring in 97.5% of Opdivo plus CABOMETYX patients vs 93.1% for sunitinib [2] - Grade ≥3 TRAEs occurred in 67.5% of Opdivo plus CABOMETYX patients vs 55.3% for sunitinib [2] - The combination demonstrated durable and clinically meaningful benefits in health-related quality of life compared to sunitinib [1] Industry and Company Impact - The results reinforce the role of Opdivo plus CABOMETYX as a first-line treatment option for advanced RCC, with potential to improve long-term survival outcomes [5][6] - Bristol Myers Squibb and Exelixis continue to collaborate on advancing treatment regimens for advanced cancers, including genitourinary cancers [5][66] - The trial results highlight the ongoing need for effective therapeutic options for patients with advanced or metastatic RCC, particularly those with challenging-to-treat disease burdens [5][6]

BALA CYNWYD, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Karuna Therapeutics, Inc. (Nasdaq – KRTX) Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash tran ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of chemotherapy (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The dual immunotherapy combination of Opdivo and Yervoy d ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tu ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $50, moving -0.62% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.37%. Elsewhere, the Dow saw a downswing of 0.62%, while the tech-heavy Nasdaq depreciated by 0.19%.The biopharmaceutical company's shares have seen a decrease of 2.01% over the last month, not keeping up with the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56%.The investment community will be paying close attent ...

BlackJack3D Yet another cheap Big Pharma stock Having recently written about the cratered pharma stock and value opportunity in Pfizer (PFE), charting the big pharma sell-offs, reveals a nearly as strong downtrend in Bristol-Myers Squibb (NYSE:BMY). The company is in a similar phase of R&D cycling and acquisitions to fill its next cycle of drugs for the next decade. Bristol Myers does not have the stigma around it from being a vaccine producer during COVID-19, but they also have their issues to reckon w ...

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced that it has formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego. The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at ...

As 2022 came to a close, investors were skeptical – to say the least. As inflation soared to 40-year highs, war broke out in Europe, a regional banking crisis gained steam and tech stocks got hammered, few Wall Street “experts” or talking heads predicted that stocks would have the bullish year they had. However, savvy investors have a way of looking past short-term gyrations in the stock market and understanding the context. While the future remains unwritten, if we look at a long-term chart of the S&P 500 ...

PM Images I have been on the hunt for value in the early days of 2024. One of my investment premises for the year is that a broad market rally will occur, and it will be led by several sectors that underperformed the market in 2023. I also think some profits from the 2023 bull market will be taken, and they will be allocated toward value in addition to capital flowing in from the sidelines trying to front-run a Fed pivot. Recently, I started a much larger position in Pfizer (PFE) outside of my Dividend ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.28, marking a -0.98% move from the previous day. This change lagged the S&P 500's 0.15% loss on the day. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq increased by 0.09%.The the stock of biopharmaceutical company has risen by 1.37% in the past month, lagging the Medical sector's gain of 6.58% and the S&P 500's gain of 3.5%.The upcoming earnings release of Bristol Myers Squibb will be of great i ...